{
  "symbol": "VRTX",
  "year": 2024,
  "competition_summary": [
    {
      "competitor": "Medicare",
      "mentions": 2,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. Additionally, in August 2022, the Inflation Reduction Act (\u201cIRA\u201d) was enacted, establishing a Medicare Drug Price Negotiation Program, a Medicare inflationary rebate, and a redesign of the Part D benefit structure. Certain orphan drugs, including our CF medicines, are excluded from the IRA negotiation program. We anticipate that the U.S. government will continue to engage in ac"
    },
    {
      "competitor": "Medicare Drug Price Negotiation Program",
      "mentions": 1,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. Additionally, in August 2022, the Inflation Reduction Act (\u201cIRA\u201d) was enacted, establishing a Medicare Drug Price Negotiation Program, a Medicare inflationary rebate, and a redesign of the Part D benefit structure. Certain orphan drugs, including our CF medicines, are excluded from the IRA negotiation program. We anticipate that the U.S. government will continue to engage in ac"
    },
    {
      "competitor": "CF",
      "mentions": 13,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. Additionally, in August 2022, the Inflation Reduction Act (\u201cIRA\u201d) was enacted, establishing a Medicare Drug Price Negotiation Program, a Medicare inflationary rebate, and a redesign of the Part D benefit structure. Certain orphan drugs, including our CF medicines, are excluded from the IRA negotiation program. We anticipate that the U.S. government will continue to engage in ac"
    },
    {
      "competitor": "Prescription Drug Affordability Boards",
      "mentions": 1,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. Additionally, in August 2022, the Inflation Reduction Act (\u201cIRA\u201d) was enacted, establishing a Medicare Drug Price Negotiation Program, a Medicare inflationary rebate, and a redesign of the Part D benefit structure. Certain orphan drugs, including our CF medicines, are excluded from the IRA negotiation program. We anticipate that the U.S. government will continue to engage in ac"
    },
    {
      "competitor": "TRIKAFTA",
      "mentions": 10,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. Additionally, in August 2022, the Inflation Reduction Act (\u201cIRA\u201d) was enacted, establishing a Medicare Drug Price Negotiation Program, a Medicare inflationary rebate, and a redesign of the Part D benefit structure. Certain orphan drugs, including our CF medicines, are excluded from the IRA negotiation program. We anticipate that the U.S. government will continue to engage in ac"
    },
    {
      "competitor": "KAFTRIO",
      "mentions": 5,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. Additionally, in August 2022, the Inflation Reduction Act (\u201cIRA\u201d) was enacted, establishing a Medicare Drug Price Negotiation Program, a Medicare inflationary rebate, and a redesign of the Part D benefit structure. Certain orphan drugs, including our CF medicines, are excluded from the IRA negotiation program. We anticipate that the U.S. government will continue to engage in ac"
    },
    {
      "competitor": "SCD",
      "mentions": 8,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. Additionally, in August 2022, the Inflation Reduction Act (\u201cIRA\u201d) was enacted, establishing a Medicare Drug Price Negotiation Program, a Medicare inflationary rebate, and a redesign of the Part D benefit structure. Certain orphan drugs, including our CF medicines, are excluded from the IRA negotiation program. We anticipate that the U.S. government will continue to engage in ac"
    },
    {
      "competitor": "TDT",
      "mentions": 4,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. Additionally, in August 2022, the Inflation Reduction Act (\u201cIRA\u201d) was enacted, establishing a Medicare Drug Price Negotiation Program, a Medicare inflationary rebate, and a redesign of the Part D benefit structure. Certain orphan drugs, including our CF medicines, are excluded from the IRA negotiation program. We anticipate that the U.S. government will continue to engage in ac"
    },
    {
      "competitor": "Medicaid",
      "mentions": 5,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. Additionally, in August 2022, the Inflation Reduction Act (\u201cIRA\u201d) was enacted, establishing a Medicare Drug Price Negotiation Program, a Medicare inflationary rebate, and a redesign of the Part D benefit structure. Certain orphan drugs, including our CF medicines, are excluded from the IRA negotiation program. We anticipate that the U.S. government will continue to engage in ac"
    },
    {
      "competitor": "the Biden Administration",
      "mentions": 1,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. Additionally, in August 2022, the Inflation Reduction Act (\u201cIRA\u201d) was enacted, establishing a Medicare Drug Price Negotiation Program, a Medicare inflationary rebate, and a redesign of the Part D benefit structure. Certain orphan drugs, including our CF medicines, are excluded from the IRA negotiation program. We anticipate that the U.S. government will continue to engage in ac"
    },
    {
      "competitor": "CMS",
      "mentions": 2,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. Additionally, in August 2022, the Inflation Reduction Act (\u201cIRA\u201d) was enacted, establishing a Medicare Drug Price Negotiation Program, a Medicare inflationary rebate, and a redesign of the Part D benefit structure. Certain orphan drugs, including our CF medicines, are excluded from the IRA negotiation program. We anticipate that the U.S. government will continue to engage in ac"
    },
    {
      "competitor": "CASGEVY",
      "mentions": 2,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. Additionally, in August 2022, the Inflation Reduction Act (\u201cIRA\u201d) was enacted, establishing a Medicare Drug Price Negotiation Program, a Medicare inflationary rebate, and a redesign of the Part D benefit structure. Certain orphan drugs, including our CF medicines, are excluded from the IRA negotiation program. We anticipate that the U.S. government will continue to engage in ac"
    },
    {
      "competitor": "ATC",
      "mentions": 2,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. Additionally, in August 2022, the Inflation Reduction Act (\u201cIRA\u201d) was enacted, establishing a Medicare Drug Price Negotiation Program, a Medicare inflationary rebate, and a redesign of the Part D benefit structure. Certain orphan drugs, including our CF medicines, are excluded from the IRA negotiation program. We anticipate that the U.S. government will continue to engage in ac"
    },
    {
      "competitor": "Concert Pharmaceuticals Inc.",
      "mentions": 1,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. Additionally, in August 2022, the Inflation Reduction Act (\u201cIRA\u201d) was enacted, establishing a Medicare Drug Price Negotiation Program, a Medicare inflationary rebate, and a redesign of the Part D benefit structure. Certain orphan drugs, including our CF medicines, are excluded from the IRA negotiation program. We anticipate that the U.S. government will continue to engage in ac"
    },
    {
      "competitor": "Semma",
      "mentions": 1,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. Additionally, in August 2022, the Inflation Reduction Act (\u201cIRA\u201d) was enacted, establishing a Medicare Drug Price Negotiation Program, a Medicare inflationary rebate, and a redesign of the Part D benefit structure. Certain orphan drugs, including our CF medicines, are excluded from the IRA negotiation program. We anticipate that the U.S. government will continue to engage in ac"
    },
    {
      "competitor": "Licensing Arrangements Joint Development and Commercialization Agreement",
      "mentions": 1,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. Additionally, in August 2022, the Inflation Reduction Act (\u201cIRA\u201d) was enacted, establishing a Medicare Drug Price Negotiation Program, a Medicare inflationary rebate, and a redesign of the Part D benefit structure. Certain orphan drugs, including our CF medicines, are excluded from the IRA negotiation program. We anticipate that the U.S. government will continue to engage in ac"
    },
    {
      "competitor": "Original JDCA",
      "mentions": 1,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. Additionally, in August 2022, the Inflation Reduction Act (\u201cIRA\u201d) was enacted, establishing a Medicare Drug Price Negotiation Program, a Medicare inflationary rebate, and a redesign of the Part D benefit structure. Certain orphan drugs, including our CF medicines, are excluded from the IRA negotiation program. We anticipate that the U.S. government will continue to engage in ac"
    },
    {
      "competitor": "CRISPR",
      "mentions": 9,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. Additionally, in August 2022, the Inflation Reduction Act (\u201cIRA\u201d) was enacted, establishing a Medicare Drug Price Negotiation Program, a Medicare inflationary rebate, and a redesign of the Part D benefit structure. Certain orphan drugs, including our CF medicines, are excluded from the IRA negotiation program. We anticipate that the U.S. government will continue to engage in ac"
    },
    {
      "competitor": "the Original JDCA",
      "mentions": 1,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. Additionally, in August 2022, the Inflation Reduction Act (\u201cIRA\u201d) was enacted, establishing a Medicare Drug Price Negotiation Program, a Medicare inflationary rebate, and a redesign of the Part D benefit structure. Certain orphan drugs, including our CF medicines, are excluded from the IRA negotiation program. We anticipate that the U.S. government will continue to engage in ac"
    },
    {
      "competitor": "the A&R JDCA",
      "mentions": 11,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. Additionally, in August 2022, the Inflation Reduction Act (\u201cIRA\u201d) was enacted, establishing a Medicare Drug Price Negotiation Program, a Medicare inflationary rebate, and a redesign of the Part D benefit structure. Certain orphan drugs, including our CF medicines, are excluded from the IRA negotiation program. We anticipate that the U.S. government will continue to engage in ac"
    },
    {
      "competitor": "FDA",
      "mentions": 10,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. Additionally, in August 2022, the Inflation Reduction Act (\u201cIRA\u201d) was enacted, establishing a Medicare Drug Price Negotiation Program, a Medicare inflationary rebate, and a redesign of the Part D benefit structure. Certain orphan drugs, including our CF medicines, are excluded from the IRA negotiation program. We anticipate that the U.S. government will continue to engage in ac"
    },
    {
      "competitor": "\u2022 CRISPR Therapeutics AG",
      "mentions": 1,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. Additionally, in August 2022, the Inflation Reduction Act (\u201cIRA\u201d) was enacted, establishing a Medicare Drug Price Negotiation Program, a Medicare inflationary rebate, and a redesign of the Part D benefit structure. Certain orphan drugs, including our CF medicines, are excluded from the IRA negotiation program. We anticipate that the U.S. government will continue to engage in ac"
    },
    {
      "competitor": "DMD",
      "mentions": 1,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. Additionally, in August 2022, the Inflation Reduction Act (\u201cIRA\u201d) was enacted, establishing a Medicare Drug Price Negotiation Program, a Medicare inflationary rebate, and a redesign of the Part D benefit structure. Certain orphan drugs, including our CF medicines, are excluded from the IRA negotiation program. We anticipate that the U.S. government will continue to engage in ac"
    },
    {
      "competitor": "Investigational New Drug Application",
      "mentions": 1,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. Additionally, in August 2022, the Inflation Reduction Act (\u201cIRA\u201d) was enacted, establishing a Medicare Drug Price Negotiation Program, a Medicare inflationary rebate, and a redesign of the Part D benefit structure. Certain orphan drugs, including our CF medicines, are excluded from the IRA negotiation program. We anticipate that the U.S. government will continue to engage in ac"
    },
    {
      "competitor": "IND",
      "mentions": 1,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. Additionally, in August 2022, the Inflation Reduction Act (\u201cIRA\u201d) was enacted, establishing a Medicare Drug Price Negotiation Program, a Medicare inflationary rebate, and a redesign of the Part D benefit structure. Certain orphan drugs, including our CF medicines, are excluded from the IRA negotiation program. We anticipate that the U.S. government will continue to engage in ac"
    },
    {
      "competitor": "Entrada",
      "mentions": 1,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. Additionally, in August 2022, the Inflation Reduction Act (\u201cIRA\u201d) was enacted, establishing a Medicare Drug Price Negotiation Program, a Medicare inflationary rebate, and a redesign of the Part D benefit structure. Certain orphan drugs, including our CF medicines, are excluded from the IRA negotiation program. We anticipate that the U.S. government will continue to engage in ac"
    },
    {
      "competitor": "Cystic Fibrosis Foundation",
      "mentions": 1,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. Additionally, in August 2022, the Inflation Reduction Act (\u201cIRA\u201d) was enacted, establishing a Medicare Drug Price Negotiation Program, a Medicare inflationary rebate, and a redesign of the Part D benefit structure. Certain orphan drugs, including our CF medicines, are excluded from the IRA negotiation program. We anticipate that the U.S. government will continue to engage in ac"
    },
    {
      "competitor": "the Cystic Fibrosis Foundation",
      "mentions": 1,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. Additionally, in August 2022, the Inflation Reduction Act (\u201cIRA\u201d) was enacted, establishing a Medicare Drug Price Negotiation Program, a Medicare inflationary rebate, and a redesign of the Part D benefit structure. Certain orphan drugs, including our CF medicines, are excluded from the IRA negotiation program. We anticipate that the U.S. government will continue to engage in ac"
    },
    {
      "competitor": "the Cystic Fibrosis Foundation Therapeutics, Inc.",
      "mentions": 1,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. Additionally, in August 2022, the Inflation Reduction Act (\u201cIRA\u201d) was enacted, establishing a Medicare Drug Price Negotiation Program, a Medicare inflationary rebate, and a redesign of the Part D benefit structure. Certain orphan drugs, including our CF medicines, are excluded from the IRA negotiation program. We anticipate that the U.S. government will continue to engage in ac"
    },
    {
      "competitor": "ORKAMBI",
      "mentions": 3,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. Additionally, in August 2022, the Inflation Reduction Act (\u201cIRA\u201d) was enacted, establishing a Medicare Drug Price Negotiation Program, a Medicare inflationary rebate, and a redesign of the Part D benefit structure. Certain orphan drugs, including our CF medicines, are excluded from the IRA negotiation program. We anticipate that the U.S. government will continue to engage in ac"
    },
    {
      "competitor": "NDA",
      "mentions": 1,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. Additionally, in August 2022, the Inflation Reduction Act (\u201cIRA\u201d) was enacted, establishing a Medicare Drug Price Negotiation Program, a Medicare inflationary rebate, and a redesign of the Part D benefit structure. Certain orphan drugs, including our CF medicines, are excluded from the IRA negotiation program. We anticipate that the U.S. government will continue to engage in ac"
    },
    {
      "competitor": "the Orange Book",
      "mentions": 5,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. Additionally, in August 2022, the Inflation Reduction Act (\u201cIRA\u201d) was enacted, establishing a Medicare Drug Price Negotiation Program, a Medicare inflationary rebate, and a redesign of the Part D benefit structure. Certain orphan drugs, including our CF medicines, are excluded from the IRA negotiation program. We anticipate that the U.S. government will continue to engage in ac"
    },
    {
      "competitor": "KALYDECO",
      "mentions": 2,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. Additionally, in August 2022, the Inflation Reduction Act (\u201cIRA\u201d) was enacted, establishing a Medicare Drug Price Negotiation Program, a Medicare inflationary rebate, and a redesign of the Part D benefit structure. Certain orphan drugs, including our CF medicines, are excluded from the IRA negotiation program. We anticipate that the U.S. government will continue to engage in ac"
    },
    {
      "competitor": "a Biologics Licensing Application",
      "mentions": 1,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. Additionally, in August 2022, the Inflation Reduction Act (\u201cIRA\u201d) was enacted, establishing a Medicare Drug Price Negotiation Program, a Medicare inflationary rebate, and a redesign of the Part D benefit structure. Certain orphan drugs, including our CF medicines, are excluded from the IRA negotiation program. We anticipate that the U.S. government will continue to engage in ac"
    },
    {
      "competitor": "BLA",
      "mentions": 1,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. Additionally, in August 2022, the Inflation Reduction Act (\u201cIRA\u201d) was enacted, establishing a Medicare Drug Price Negotiation Program, a Medicare inflationary rebate, and a redesign of the Part D benefit structure. Certain orphan drugs, including our CF medicines, are excluded from the IRA negotiation program. We anticipate that the U.S. government will continue to engage in ac"
    },
    {
      "competitor": "Orange Book",
      "mentions": 1,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. Additionally, in August 2022, the Inflation Reduction Act (\u201cIRA\u201d) was enacted, establishing a Medicare Drug Price Negotiation Program, a Medicare inflationary rebate, and a redesign of the Part D benefit structure. Certain orphan drugs, including our CF medicines, are excluded from the IRA negotiation program. We anticipate that the U.S. government will continue to engage in ac"
    },
    {
      "competitor": "SYMDEKO/SYMKEVI",
      "mentions": 1,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. Additionally, in August 2022, the Inflation Reduction Act (\u201cIRA\u201d) was enacted, establishing a Medicare Drug Price Negotiation Program, a Medicare inflationary rebate, and a redesign of the Part D benefit structure. Certain orphan drugs, including our CF medicines, are excluded from the IRA negotiation program. We anticipate that the U.S. government will continue to engage in ac"
    },
    {
      "competitor": "U.S. Basic Product Patent Expiration Year",
      "mentions": 1,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. Additionally, in August 2022, the Inflation Reduction Act (\u201cIRA\u201d) was enacted, establishing a Medicare Drug Price Negotiation Program, a Medicare inflationary rebate, and a redesign of the Part D benefit structure. Certain orphan drugs, including our CF medicines, are excluded from the IRA negotiation program. We anticipate that the U.S. government will continue to engage in ac"
    },
    {
      "competitor": "AATD",
      "mentions": 1,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. Additionally, in August 2022, the Inflation Reduction Act (\u201cIRA\u201d) was enacted, establishing a Medicare Drug Price Negotiation Program, a Medicare inflationary rebate, and a redesign of the Part D benefit structure. Certain orphan drugs, including our CF medicines, are excluded from the IRA negotiation program. We anticipate that the U.S. government will continue to engage in ac"
    },
    {
      "competitor": "the University of California or",
      "mentions": 1,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. Additionally, in August 2022, the Inflation Reduction Act (\u201cIRA\u201d) was enacted, establishing a Medicare Drug Price Negotiation Program, a Medicare inflationary rebate, and a redesign of the Part D benefit structure. Certain orphan drugs, including our CF medicines, are excluded from the IRA negotiation program. We anticipate that the U.S. government will continue to engage in ac"
    },
    {
      "competitor": "the University of Vienna",
      "mentions": 1,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. Additionally, in August 2022, the Inflation Reduction Act (\u201cIRA\u201d) was enacted, establishing a Medicare Drug Price Negotiation Program, a Medicare inflationary rebate, and a redesign of the Part D benefit structure. Certain orphan drugs, including our CF medicines, are excluded from the IRA negotiation program. We anticipate that the U.S. government will continue to engage in ac"
    },
    {
      "competitor": "the CVC Group",
      "mentions": 4,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. Additionally, in August 2022, the Inflation Reduction Act (\u201cIRA\u201d) was enacted, establishing a Medicare Drug Price Negotiation Program, a Medicare inflationary rebate, and a redesign of the Part D benefit structure. Certain orphan drugs, including our CF medicines, are excluded from the IRA negotiation program. We anticipate that the U.S. government will continue to engage in ac"
    },
    {
      "competitor": "Trademark Office",
      "mentions": 1,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. Additionally, in August 2022, the Inflation Reduction Act (\u201cIRA\u201d) was enacted, establishing a Medicare Drug Price Negotiation Program, a Medicare inflationary rebate, and a redesign of the Part D benefit structure. Certain orphan drugs, including our CF medicines, are excluded from the IRA negotiation program. We anticipate that the U.S. government will continue to engage in ac"
    },
    {
      "competitor": "LLC",
      "mentions": 1,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. Additionally, in August 2022, the Inflation Reduction Act (\u201cIRA\u201d) was enacted, establishing a Medicare Drug Price Negotiation Program, a Medicare inflationary rebate, and a redesign of the Part D benefit structure. Certain orphan drugs, including our CF medicines, are excluded from the IRA negotiation program. We anticipate that the U.S. government will continue to engage in ac"
    },
    {
      "competitor": "ToolGen, Inc.",
      "mentions": 1,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. Additionally, in August 2022, the Inflation Reduction Act (\u201cIRA\u201d) was enacted, establishing a Medicare Drug Price Negotiation Program, a Medicare inflationary rebate, and a redesign of the Part D benefit structure. Certain orphan drugs, including our CF medicines, are excluded from the IRA negotiation program. We anticipate that the U.S. government will continue to engage in ac"
    },
    {
      "competitor": "the Broad Institute",
      "mentions": 1,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. Additionally, in August 2022, the Inflation Reduction Act (\u201cIRA\u201d) was enacted, establishing a Medicare Drug Price Negotiation Program, a Medicare inflationary rebate, and a redesign of the Part D benefit structure. Certain orphan drugs, including our CF medicines, are excluded from the IRA negotiation program. We anticipate that the U.S. government will continue to engage in ac"
    },
    {
      "competitor": "Harvard University",
      "mentions": 1,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. Additionally, in August 2022, the Inflation Reduction Act (\u201cIRA\u201d) was enacted, establishing a Medicare Drug Price Negotiation Program, a Medicare inflationary rebate, and a redesign of the Part D benefit structure. Certain orphan drugs, including our CF medicines, are excluded from the IRA negotiation program. We anticipate that the U.S. government will continue to engage in ac"
    },
    {
      "competitor": "Massachusetts Institute of Technology",
      "mentions": 1,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. Additionally, in August 2022, the Inflation Reduction Act (\u201cIRA\u201d) was enacted, establishing a Medicare Drug Price Negotiation Program, a Medicare inflationary rebate, and a redesign of the Part D benefit structure. Certain orphan drugs, including our CF medicines, are excluded from the IRA negotiation program. We anticipate that the U.S. government will continue to engage in ac"
    },
    {
      "competitor": "Editas Medicine, Inc.",
      "mentions": 1,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. Additionally, in August 2022, the Inflation Reduction Act (\u201cIRA\u201d) was enacted, establishing a Medicare Drug Price Negotiation Program, a Medicare inflationary rebate, and a redesign of the Part D benefit structure. Certain orphan drugs, including our CF medicines, are excluded from the IRA negotiation program. We anticipate that the U.S. government will continue to engage in ac"
    },
    {
      "competitor": "CRISPR/Cas9",
      "mentions": 2,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. Additionally, in August 2022, the Inflation Reduction Act (\u201cIRA\u201d) was enacted, establishing a Medicare Drug Price Negotiation Program, a Medicare inflationary rebate, and a redesign of the Part D benefit structure. Certain orphan drugs, including our CF medicines, are excluded from the IRA negotiation program. We anticipate that the U.S. government will continue to engage in ac"
    },
    {
      "competitor": "Broad",
      "mentions": 1,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. Additionally, in August 2022, the Inflation Reduction Act (\u201cIRA\u201d) was enacted, establishing a Medicare Drug Price Negotiation Program, a Medicare inflationary rebate, and a redesign of the Part D benefit structure. Certain orphan drugs, including our CF medicines, are excluded from the IRA negotiation program. We anticipate that the U.S. government will continue to engage in ac"
    },
    {
      "competitor": "Harvard",
      "mentions": 2,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. Additionally, in August 2022, the Inflation Reduction Act (\u201cIRA\u201d) was enacted, establishing a Medicare Drug Price Negotiation Program, a Medicare inflationary rebate, and a redesign of the Part D benefit structure. Certain orphan drugs, including our CF medicines, are excluded from the IRA negotiation program. We anticipate that the U.S. government will continue to engage in ac"
    },
    {
      "competitor": "inter partes",
      "mentions": 1,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. Additionally, in August 2022, the Inflation Reduction Act (\u201cIRA\u201d) was enacted, establishing a Medicare Drug Price Negotiation Program, a Medicare inflationary rebate, and a redesign of the Part D benefit structure. Certain orphan drugs, including our CF medicines, are excluded from the IRA negotiation program. We anticipate that the U.S. government will continue to engage in ac"
    },
    {
      "competitor": "T1D.",
      "mentions": 1,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. Additionally, in August 2022, the Inflation Reduction Act (\u201cIRA\u201d) was enacted, establishing a Medicare Drug Price Negotiation Program, a Medicare inflationary rebate, and a redesign of the Part D benefit structure. Certain orphan drugs, including our CF medicines, are excluded from the IRA negotiation program. We anticipate that the U.S. government will continue to engage in ac"
    },
    {
      "competitor": "CFTR",
      "mentions": 6,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. Additionally, in August 2022, the Inflation Reduction Act (\u201cIRA\u201d) was enacted, establishing a Medicare Drug Price Negotiation Program, a Medicare inflationary rebate, and a redesign of the Part D benefit structure. Certain orphan drugs, including our CF medicines, are excluded from the IRA negotiation program. We anticipate that the U.S. government will continue to engage in ac"
    },
    {
      "competitor": "Proteostasis Therapeutics, Inc.",
      "mentions": 1,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. Additionally, in August 2022, the Inflation Reduction Act (\u201cIRA\u201d) was enacted, establishing a Medicare Drug Price Negotiation Program, a Medicare inflationary rebate, and a redesign of the Part D benefit structure. Certain orphan drugs, including our CF medicines, are excluded from the IRA negotiation program. We anticipate that the U.S. government will continue to engage in ac"
    },
    {
      "competitor": "Yumanity Therapeutics, Inc.",
      "mentions": 1,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. Additionally, in August 2022, the Inflation Reduction Act (\u201cIRA\u201d) was enacted, establishing a Medicare Drug Price Negotiation Program, a Medicare inflationary rebate, and a redesign of the Part D benefit structure. Certain orphan drugs, including our CF medicines, are excluded from the IRA negotiation program. We anticipate that the U.S. government will continue to engage in ac"
    },
    {
      "competitor": "Fair Therapeutics",
      "mentions": 2,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. Additionally, in August 2022, the Inflation Reduction Act (\u201cIRA\u201d) was enacted, establishing a Medicare Drug Price Negotiation Program, a Medicare inflationary rebate, and a redesign of the Part D benefit structure. Certain orphan drugs, including our CF medicines, are excluded from the IRA negotiation program. We anticipate that the U.S. government will continue to engage in ac"
    },
    {
      "competitor": "HIT-CF Europe",
      "mentions": 1,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. Additionally, in August 2022, the Inflation Reduction Act (\u201cIRA\u201d) was enacted, establishing a Medicare Drug Price Negotiation Program, a Medicare inflationary rebate, and a redesign of the Part D benefit structure. Certain orphan drugs, including our CF medicines, are excluded from the IRA negotiation program. We anticipate that the U.S. government will continue to engage in ac"
    },
    {
      "competitor": "CF-Europe",
      "mentions": 1,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. Additionally, in August 2022, the Inflation Reduction Act (\u201cIRA\u201d) was enacted, establishing a Medicare Drug Price Negotiation Program, a Medicare inflationary rebate, and a redesign of the Part D benefit structure. Certain orphan drugs, including our CF medicines, are excluded from the IRA negotiation program. We anticipate that the U.S. government will continue to engage in ac"
    },
    {
      "competitor": "Phase 1",
      "mentions": 1,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. Additionally, in August 2022, the Inflation Reduction Act (\u201cIRA\u201d) was enacted, establishing a Medicare Drug Price Negotiation Program, a Medicare inflationary rebate, and a redesign of the Part D benefit structure. Certain orphan drugs, including our CF medicines, are excluded from the IRA negotiation program. We anticipate that the U.S. government will continue to engage in ac"
    },
    {
      "competitor": "Arcturus Therapeutics Holdings, Inc.",
      "mentions": 1,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. Additionally, in August 2022, the Inflation Reduction Act (\u201cIRA\u201d) was enacted, establishing a Medicare Drug Price Negotiation Program, a Medicare inflationary rebate, and a redesign of the Part D benefit structure. Certain orphan drugs, including our CF medicines, are excluded from the IRA negotiation program. We anticipate that the U.S. government will continue to engage in ac"
    },
    {
      "competitor": "ReCode Therapeutics, Inc.",
      "mentions": 1,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. Additionally, in August 2022, the Inflation Reduction Act (\u201cIRA\u201d) was enacted, establishing a Medicare Drug Price Negotiation Program, a Medicare inflationary rebate, and a redesign of the Part D benefit structure. Certain orphan drugs, including our CF medicines, are excluded from the IRA negotiation program. We anticipate that the U.S. government will continue to engage in ac"
    },
    {
      "competitor": "Krystal Biotech, Inc.",
      "mentions": 1,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. Additionally, in August 2022, the Inflation Reduction Act (\u201cIRA\u201d) was enacted, establishing a Medicare Drug Price Negotiation Program, a Medicare inflationary rebate, and a redesign of the Part D benefit structure. Certain orphan drugs, including our CF medicines, are excluded from the IRA negotiation program. We anticipate that the U.S. government will continue to engage in ac"
    },
    {
      "competitor": "Spirovant Sciences",
      "mentions": 1,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. Additionally, in August 2022, the Inflation Reduction Act (\u201cIRA\u201d) was enacted, establishing a Medicare Drug Price Negotiation Program, a Medicare inflationary rebate, and a redesign of the Part D benefit structure. Certain orphan drugs, including our CF medicines, are excluded from the IRA negotiation program. We anticipate that the U.S. government will continue to engage in ac"
    },
    {
      "competitor": "Boehringer Ingelheim International",
      "mentions": 1,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. Additionally, in August 2022, the Inflation Reduction Act (\u201cIRA\u201d) was enacted, establishing a Medicare Drug Price Negotiation Program, a Medicare inflationary rebate, and a redesign of the Part D benefit structure. Certain orphan drugs, including our CF medicines, are excluded from the IRA negotiation program. We anticipate that the U.S. government will continue to engage in ac"
    },
    {
      "competitor": "GmbH",
      "mentions": 1,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. Additionally, in August 2022, the Inflation Reduction Act (\u201cIRA\u201d) was enacted, establishing a Medicare Drug Price Negotiation Program, a Medicare inflationary rebate, and a redesign of the Part D benefit structure. Certain orphan drugs, including our CF medicines, are excluded from the IRA negotiation program. We anticipate that the U.S. government will continue to engage in ac"
    },
    {
      "competitor": "4D Molecular Therapeutics, Inc and",
      "mentions": 1,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. Additionally, in August 2022, the Inflation Reduction Act (\u201cIRA\u201d) was enacted, establishing a Medicare Drug Price Negotiation Program, a Medicare inflationary rebate, and a redesign of the Part D benefit structure. Certain orphan drugs, including our CF medicines, are excluded from the IRA negotiation program. We anticipate that the U.S. government will continue to engage in ac"
    },
    {
      "competitor": "Novartis International AG",
      "mentions": 1,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. Additionally, in August 2022, the Inflation Reduction Act (\u201cIRA\u201d) was enacted, establishing a Medicare Drug Price Negotiation Program, a Medicare inflationary rebate, and a redesign of the Part D benefit structure. Certain orphan drugs, including our CF medicines, are excluded from the IRA negotiation program. We anticipate that the U.S. government will continue to engage in ac"
    },
    {
      "competitor": "Pfizer Inc.",
      "mentions": 1,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. Additionally, in August 2022, the Inflation Reduction Act (\u201cIRA\u201d) was enacted, establishing a Medicare Drug Price Negotiation Program, a Medicare inflationary rebate, and a redesign of the Part D benefit structure. Certain orphan drugs, including our CF medicines, are excluded from the IRA negotiation program. We anticipate that the U.S. government will continue to engage in ac"
    },
    {
      "competitor": "Bristol Myers Squibb",
      "mentions": 1,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. Additionally, in August 2022, the Inflation Reduction Act (\u201cIRA\u201d) was enacted, establishing a Medicare Drug Price Negotiation Program, a Medicare inflationary rebate, and a redesign of the Part D benefit structure. Certain orphan drugs, including our CF medicines, are excluded from the IRA negotiation program. We anticipate that the U.S. government will continue to engage in ac"
    },
    {
      "competitor": "Merck & Co.",
      "mentions": 1,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. Additionally, in August 2022, the Inflation Reduction Act (\u201cIRA\u201d) was enacted, establishing a Medicare Drug Price Negotiation Program, a Medicare inflationary rebate, and a redesign of the Part D benefit structure. Certain orphan drugs, including our CF medicines, are excluded from the IRA negotiation program. We anticipate that the U.S. government will continue to engage in ac"
    },
    {
      "competitor": "bio, Inc.",
      "mentions": 1,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. Additionally, in August 2022, the Inflation Reduction Act (\u201cIRA\u201d) was enacted, establishing a Medicare Drug Price Negotiation Program, a Medicare inflationary rebate, and a redesign of the Part D benefit structure. Certain orphan drugs, including our CF medicines, are excluded from the IRA negotiation program. We anticipate that the U.S. government will continue to engage in ac"
    },
    {
      "competitor": "Orion Corporation",
      "mentions": 1,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. Additionally, in August 2022, the Inflation Reduction Act (\u201cIRA\u201d) was enacted, establishing a Medicare Drug Price Negotiation Program, a Medicare inflationary rebate, and a redesign of the Part D benefit structure. Certain orphan drugs, including our CF medicines, are excluded from the IRA negotiation program. We anticipate that the U.S. government will continue to engage in ac"
    },
    {
      "competitor": "Merck",
      "mentions": 1,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. Additionally, in August 2022, the Inflation Reduction Act (\u201cIRA\u201d) was enacted, establishing a Medicare Drug Price Negotiation Program, a Medicare inflationary rebate, and a redesign of the Part D benefit structure. Certain orphan drugs, including our CF medicines, are excluded from the IRA negotiation program. We anticipate that the U.S. government will continue to engage in ac"
    },
    {
      "competitor": "Gr\u00fcnenthal",
      "mentions": 1,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. Additionally, in August 2022, the Inflation Reduction Act (\u201cIRA\u201d) was enacted, establishing a Medicare Drug Price Negotiation Program, a Medicare inflationary rebate, and a redesign of the Part D benefit structure. Certain orphan drugs, including our CF medicines, are excluded from the IRA negotiation program. We anticipate that the U.S. government will continue to engage in ac"
    },
    {
      "competitor": "CellTrans",
      "mentions": 1,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. Additionally, in August 2022, the Inflation Reduction Act (\u201cIRA\u201d) was enacted, establishing a Medicare Drug Price Negotiation Program, a Medicare inflationary rebate, and a redesign of the Part D benefit structure. Certain orphan drugs, including our CF medicines, are excluded from the IRA negotiation program. We anticipate that the U.S. government will continue to engage in ac"
    },
    {
      "competitor": "Eli Lilly & Co.",
      "mentions": 1,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. Additionally, in August 2022, the Inflation Reduction Act (\u201cIRA\u201d) was enacted, establishing a Medicare Drug Price Negotiation Program, a Medicare inflationary rebate, and a redesign of the Part D benefit structure. Certain orphan drugs, including our CF medicines, are excluded from the IRA negotiation program. We anticipate that the U.S. government will continue to engage in ac"
    },
    {
      "competitor": "Sernova Corp",
      "mentions": 1,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. Additionally, in August 2022, the Inflation Reduction Act (\u201cIRA\u201d) was enacted, establishing a Medicare Drug Price Negotiation Program, a Medicare inflationary rebate, and a redesign of the Part D benefit structure. Certain orphan drugs, including our CF medicines, are excluded from the IRA negotiation program. We anticipate that the U.S. government will continue to engage in ac"
    },
    {
      "competitor": "Seraxis, Inc.",
      "mentions": 1,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. Additionally, in August 2022, the Inflation Reduction Act (\u201cIRA\u201d) was enacted, establishing a Medicare Drug Price Negotiation Program, a Medicare inflationary rebate, and a redesign of the Part D benefit structure. Certain orphan drugs, including our CF medicines, are excluded from the IRA negotiation program. We anticipate that the U.S. government will continue to engage in ac"
    },
    {
      "competitor": "AstraZeneca",
      "mentions": 1,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. Additionally, in August 2022, the Inflation Reduction Act (\u201cIRA\u201d) was enacted, establishing a Medicare Drug Price Negotiation Program, a Medicare inflationary rebate, and a redesign of the Part D benefit structure. Certain orphan drugs, including our CF medicines, are excluded from the IRA negotiation program. We anticipate that the U.S. government will continue to engage in ac"
    },
    {
      "competitor": "Eli Lilly and Company\u2019s Janus",
      "mentions": 1,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. Additionally, in August 2022, the Inflation Reduction Act (\u201cIRA\u201d) was enacted, establishing a Medicare Drug Price Negotiation Program, a Medicare inflationary rebate, and a redesign of the Part D benefit structure. Certain orphan drugs, including our CF medicines, are excluded from the IRA negotiation program. We anticipate that the U.S. government will continue to engage in ac"
    },
    {
      "competitor": "Phase 2",
      "mentions": 1,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. Additionally, in August 2022, the Inflation Reduction Act (\u201cIRA\u201d) was enacted, establishing a Medicare Drug Price Negotiation Program, a Medicare inflationary rebate, and a redesign of the Part D benefit structure. Certain orphan drugs, including our CF medicines, are excluded from the IRA negotiation program. We anticipate that the U.S. government will continue to engage in ac"
    },
    {
      "competitor": "Duke University",
      "mentions": 1,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. Additionally, in August 2022, the Inflation Reduction Act (\u201cIRA\u201d) was enacted, establishing a Medicare Drug Price Negotiation Program, a Medicare inflationary rebate, and a redesign of the Part D benefit structure. Certain orphan drugs, including our CF medicines, are excluded from the IRA negotiation program. We anticipate that the U.S. government will continue to engage in ac"
    }
  ]
}